All In Biotech

Drug Trial Radar · NCT06838338

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

A Phase Ib, Open Lable, Clinical Trial of JAB-21822 Combined With Second Line Chemotherapy and Bevacizumab for Metastatic Colorectal Cancer With KRAS G12C Mutation

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Mar 20, 2025

Primary completion

Mar 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Jian LiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard chemotherapy and bevacizumab in advanced colorectal cancer failed to standard therapy in Chinese population.

Conditions

  • Colorectal Cancer

Interventions

  • JAB-21822Drug

    Tablet, oral, 800 mg/QD, until PD or intolerable toxicity

  • standard second-line chemotherapyDrug

    The second line standard chemotherapy regimen recommended by clinical practice

  • BevacizumabDrug

    5mg/kg every two weeks (according to the assessment by investigator)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Time Frame: up to 1year

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University

    Hohhot, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.